USNA

USANA Health Sciences Inc. - 10-Q Summary (Quarter Ended July 1, 2006)

Business Context and Reporting Period

This report covers the quarterly period ended July 1, 2006, and the six months ended July 1, 2006. USANA Health Sciences, Inc. develops, manufactures, and distributes nutritional, weight management, and personal care products primarily through a network marketing system using independent "Associates." The company operates two reportable segments: Direct Selling (primary business) and Contract Manufacturing. As of July 1, 2006, the company had 142,000 active Associates and 75,000 active Preferred Customers worldwide.

Key Financial Metrics

Liquidity & Debt: The company had no outstanding debt as of July 1, 2006. A credit facility was amended during the quarter, increasing the line of credit from $10 million to $25 million. Net working capital decreased to $7.4 million from $15.3 million at year-end 2005, primarily due to share repurchases.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 14.5% in Q2 2006 and 15.7% for the six-month period compared to the prior year. Growth was driven by the Direct Selling segment, particularly in North America (up 19.0% in Q2) and the Pacific Rim (up 4.8% in Q2).
• Accounting Change: Effective January 1, 2006, the company adopted SFAS No. 123(R), requiring the recognition of equity-based compensation expense. This reduced net earnings by $819,000 in Q2 and $1.5 million for the six months ended July 1, 2006.
• Customer Base: Active Associates increased 13.6% year-over-year to 142,000. Active Preferred Customers increased 13.6% to 75,000.
• Contract Manufacturing: Sales in this segment increased 28.6% in Q2, attributed to fulfilling backlogged orders. Management expects this segment to stabilize between $1.5 million and $2.0 million per quarter.

Guidance, Outlook, and Risks

• Q3 2006 Guidance: Management expects consolidated net sales between $94 million and $96 million. Diluted EPS is expected to be between $0.55 and $0.57.
• Fiscal Year 2006 Guidance: Consolidated net sales growth is expected between 15% and 17%. Diluted EPS growth is expected between 17% and 20% (excluding equity-based compensation impact).
• Market Expansion: Guidance was adjusted to remove expectations for opening a new market due to licensing difficulties.
• Key Risks: Significant risks include reliance on the network marketing model, high turnover of Associates, government scrutiny of network marketing practices, foreign currency fluctuations (53.9% of sales are international), and raw material supply shortages.
• Capital Projects: The company is expanding its corporate headquarters, with a total estimated investment of $13 million. Approximately $867,000 had been invested as of July 1, 2006.

Investor Verification Checklist

• Equity Compensation Impact: Verify the long-term impact of SFAS 123(R) adoption on future earnings, with $17.8 million of unrecognized compensation expense remaining.
• Share Repurchase Activity: Confirm the remaining authorized amount for share repurchases ($10.65 million as of July 1, 2006) and its effect on cash liquidity.
• Associate Retention: Monitor the 13.6% growth in active Associates against the risk of high turnover inherent in network marketing.
• Contract Manufacturing Viability: Assess the sustainability of the Contract Manufacturing segment, which currently yields minimal margins and is primarily intended to support the Sensé product line.
• Foreign Currency Exposure: Review hedging strategies given that over 50% of sales are generated outside the U.S. and are subject to exchange rate volatility.